An Open-labeled Trial of Ramipril in Patients With Migraine

Seoul National University

Status and phase: Completed; Phase 2

Conditions: Migraine With Hypertension

Treatments: Drug: Ramipril

Study type: Interventional

Funder types: Other

Identifiers

NCT01402479

0408-131-005

Details and patient eligibility

About

Physiology of migraine involving renin-angiotensin systems (RAS) has been implicated. Ramipril is a broadly-used angiotensin-converting enzyme inhibitor. The investigators attempt to test the efficacy of ramipril on the prophylaxis of migraine attacks.

Enrollment: 50 patients

Sex: All

Ages: 20 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with chronic migraine are included in this study. Migraineurs should be aged 20 to 70 years old with the ability to read and understand the self-report scales, including the headache diary, used in this study.

Exclusion criteria

1. Medication overuse headache are excluded in this study.
2. Treatment with other ACEI or medication that may affect ARS
3. Treatment with migraine prophylactic medications or anti-hypertensive agents including β adrenergic receptor or calcium channel blockers
4. Past history of hepatic or renal dysfunction; an abnormal electrocardiography; a psychiatric disorder; a history of substance abuse; pregnancy or lactation; use of anti-psychotics, antidepressants, or anti-anxiety drugs.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

ramipril

Active Comparator group

Description:

open label single arm trial

Treatment:

Drug: Ramipril